Hypertension – Adult – Clinical Practice Guideline

Total Page:16

File Type:pdf, Size:1020Kb

Hypertension – Adult – Clinical Practice Guideline Hypertension – Adult – Clinical Practice Guideline Table of Contents EXECUTIVE SUMMARY ........................................................................................................... 3 SCOPE ...................................................................................................................................... 4 METHODOLOGY ...................................................................................................................... 5 INTRODUCTION ....................................................................................................................... 5 RECOMMENDATIONS .............................................................................................................. 5 Establish the Diagnosis ........................................................................................... 5 Patient Evaluation ................................................................................................... 7 Treatment Goals ..................................................................................................... 7 Lifestyle Modifications ............................................................................................. 8 Table 4 – Lifestyle Modifications ........................................................................ 9 Medication Treatment............................................................................................ 11 Figure 1 - Initiation and Titration of Antihypertensive Medication ..................... 13 Table 7 - Antihypertensive Doses and Adjustment Schedules ......................... 14 Laboratory Evaluations.......................................................................................... 15 BENEFITS/HARMS OF IMPLEMENTATION ...........................................................................15 IMPLEMENTATION TOOLS/PLAN ..........................................................................................15 DISCLAIMER............................................................................................................................16 PATIENT AND PROVIDER RESOURCES ...............................................................................16 REFERENCES .........................................................................................................................16 Note: Active Table of Contents Guideline Contact for Content: Guideline Contact for Changes: Name: Heather Johnson, MD, MS Name: Lee Vermeulen Phone Number: 608-263-0836 Phone Number: 608-262-7537 Email: [email protected] Email: [email protected] 1 Coordinating Team Members: Heather Johnson, MD, MS, UW Health Preventive Cardiology, ASH Clinical Specialist in Hypertension James Stein, MD, Director, UW Health Preventive Cardiology and Advanced Hypertension Program Patrick McBride, MD, MPH, Co-Director, UW Health Preventive Cardiology Matt Tattersall, DO, Cardiology Paul Kellerman, MD, FACP, FNKF, Nephrology, ASH Clinical Specialist in Hypertension William Heifner, MD, Family Medicine Lorna Belsky, MD, Internal Medicine Michael Thom, MD, Internal Medicine Elizabeth Chapman, MD, Geriatrics Teresa Darcy, MD, Clinical Lab Jennifer Passini, MD, Hospitalist Diane Wendland, MD, Hospitalist Vonda Shaw, MS, MPH, Outpatient Preventive Cardiology & Rehabilitation Manager Katie Willenborg, PharmD, Inpatient Pharmacy Cindy Gaston, PharmD, UW Health Drug Policy Program Carl Nelson, PharmD, Unity Deb Barnish, RN, Cardiology Clinic Manager Jill Lindwall, RN, Clinical Staff Education Cindy Leeder, RN, Patient Education Stephanie Kraus, CNS, Inpatient Nursing Elaine Rosenblatt, Unity Heidi Wolf, Unity Lisa Sherven, GHC Nikki Nellen, Physicians Plus Julie Utter, Dean Care Review Individuals/Bodies: UW Health Preventive Cardiology Program, UW Health Hypertension Guideline and Registry Committee Committee Approvals/Date: Clinical Knowledge Management Council 2/27/14 Release Date: 3/7/2014 2 Guideline Title: Hypertension – Adult – Clinical Practice Guideline Executive Summary Guideline Overview A UW Health multi-disciplinary group has developed this clinical practice guideline to assist in identifying, diagnosing, treating, and monitoring adults 18 years and older with hypertension. Target Population Adult patients 18 years of age and older with hypertension Practice Recommendations 1. Lifestyle modifications are the cornerstone of treatment for every patient. See Table 4 (Lifestyle Modifications). Educate all patients to limit their sodium intake to 1500 to 2000 mg/day. 2. Patients with a new diagnosis of hypertension should have an evaluation for possible secondary causes of hypertension, especially obstructive sleep apnea. 3. An ACE-inhibitor (or angiotensin receptor blocker) and/or a calcium channel blocker may be a more effective initial medication regimen than a thiazide or thiazide-type diuretic. 4. Chlorthalidone (12.5 to 25 mg daily) is the preferred thiazide-type diuretic, rather than hydrochlorothiazide (HCTZ). 5. Consider 24-hour ambulatory blood pressure monitoring* or extended home blood pressure monitoring for patients in whom white-coat or masked hypertension is suspected, or in whom the diagnosis of hypertension or need for medications is uncertain (services offered by UW Preventive Cardiology 263-7420). * 24 hour ambulatory BP monitoring and home BP monitors may not be covered by insurance. Companion Documents None Pertinent UW Health Policies & Procedures UW Medical Foundation Blood Pressure Measurement Policy https://uconnect.wisc.edu/servlet/Satellite?cid=1121776129045&pagename=B_E XTRANET_UWHC_POLICIES%2FFlexMember%2FShow_Policy&c=FlexMembe r 3 Scope Disease/Condition(s): This Clinical Practice Guideline (CPG) focuses on hypertension in adult patients ages 18 years and older. The recommendations contained within this document do not apply to patients who are pregnant. Clinical Specialty: The following clinical specialties may reference this CPG: Internal Medicine, Family Practice, Obstetrics/Gynecology, Cardiovascular Medicine, Nephrology, Neurology, Vascular Surgery, Cardiothoracic Surgery, and Neurosurgery. Intended Users: Physicians, Nurse Practitioners/Advanced Practice Nurses, Physician Assistants CPG objective(s): To reduce the incidence of stroke, myocardial infarction, congestive heart failure, and kidney failure by appropriately identifying and treating hypertension. Interventions and Practices Considered: Screening for hypertension, lifestyle assessment and modification, appropriate blood pressure monitoring, medication therapy, and ongoing care of patients diagnosed with hypertension. Major Outcomes Considered: Prevention of the complications of hypertension. Guideline Metrics - Hypertension Performance Measures: Percentage of patients 18-79 years old with a diagnosis of hypertension whose blood pressure was <140/90 mmHg and percentage of patients ≥80 years old with a diagnosis of hypertension whose blood pressure was <150/90 mmHg during the measurement year (Based on ASH/ISH Guidelines1). The recommendations within this document meet or exceed most all externally reported metrics with the exception of target BP goals for patients >80 and those with CKD and/or diabetes. 4 Methodology The UW Health Hypertension – Adult – Clinical Practice Guideline was developed in 2007 by Patrick McBride, MD, MPH and James Stein, MD of the UW Health Preventive Cardiology Program: “Recognizing & Treating Hypertension – 2007 Clinical Practice Guidelines for Adults ≥18 years old”. In preparation for this clinical practice update, the committee reviewed the 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report, a report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Additional trials and hypertension data not incorporated by the JNC 8 panel were also reviewed. After comprehensive evaluation, the committee agreed that the 2014 update of the UW Health Hypertension – Adult – Clinical Practice Guideline will be based on the 2013 Clinical Practice Guidelines for the Management of Hypertension in the Community: A statement by the American Society of Hypertension and the International Society of Hypertension, a document which currently reflects the clinical practice consensus of this committee. Cost Analysis: No formal cost analysis was performed. Introduction Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately. Patients want to be assured that blood pressure (BP) treatment will reduce their disease burden, while clinicians want guidance on hypertension management using the best scientific evidence. This guideline takes a rigorous, evidence-based approach to recommend treatment thresholds, goals, and use of medications in the management of hypertension in adults. Evidence was drawn from randomized controlled trials, which represent the gold standard for determining efficacy and effectiveness. Recommendations Establish the Diagnosis 1.1. Blood pressure should be measured at each health care encounter. The diagnosis of hypertension should be based on the presence of elevated blood pressures readings (≥140/90 mmHg in a clinic setting) on two or more visits. Consider all blood pressure measurements in the clinical context of the patient. Follow-up for an elevated blood pressure should be completed within one month. When blood pressure is at goal, routine blood pressure measurements should be taken every 6 months. 1.2. Blood pressures
Recommended publications
  • Unit 10 Shock,Resuscitation Part A
    Vanderbilt University Medical Center Emergency General Surgery Service Surgical Residency Rotation and Curriculum UNIT 10SHOCK, RESUSCITATION, AND SURGICAL CRITICAL CARE PART A: SHOCK AND RESUSCITATION UNIT OBJECTIVES: 1. Demonstrate an understanding of the pathophysiology of shock and its categories. 2. Demonstrate an understanding of the mechanisms and pathophysiology of cardiopulmonary arrest. 3. Demonstrate the ability to manage the treatment of shock and cardiopulmonary arrest. COMPETENCY-BASED KNOWLEDGE OBJECTIVES: 1. Define the categories of shock based upon type, and explain the etiology and pathophysiology of each type of shock: a. Cardiogenic b. Hypovolemic c. Distributive (septic, anaphylactic, neurogenic, and adrenal insufficiency mediated) d. Obstructive (cardiac tamponade, tension pneumothorax, pulmonary embolus) 2. Summarize the clinical presentation and hemodynamic parameters associated with each type of shock. 3. Propose an algorithm for diagnosing and initiating treatment for each shock type. 4. Discuss the pathophysiology, including the mechanism of arrest, for each of the following situations: a. Acute myocardial infarction f. Substance abuse b. Acute dysrhythmia g. Hypothermia c. Congestive heart failure h. Acute stroke d. Pulmonary embolus i. Hemorrhagic shock e. Tension pneumothorax 5. Explain the indications for and the pharmacokinetics of each of the following drugs: a. Lidocaine g. Quinidine b. Bretylium h. Isoproterenol c. Digoxin i. Amiodarone d. Propanolol j. Dopamine e. Verapamil k. Dobutamine f. Pronestyl l. Adenosine (Adenocard®) 6. Summarize the indications and the appropriate techniques for cardioversion and defibrillation. Vanderbilt University Medical Center Emergency General Surgery Service Surgical Residency Rotation and Curriculum 7. Outline the signs and symptoms of acute airway obstruction and define the appropriate intervention in adult and pediatric patients.
    [Show full text]
  • Complex Hypertension
    COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension ¨ About 70 million American adults have high blood pressure. About 33% of the population ¨ Only 52% have BP under control. ¨ Nearly a third of US adults have prehypertension. ¨ Hypertension costs $46 billion a year. (healthcare services, medications, missed work) From CDC Blood Pressure Facts 2015 What is Hypertension? ¨ JNC 7 (1997) definitions Stages Systolic Diastolic Prehypertension 102-129 OR 80-89 High BP Stage 1 140-159 OR 90-99 High BP Stage 2 160 or higher OR 100 or higher ¨ JNC 7 Goal BP = <140/90 ¨ JNC 8: did not define classification ¤ Patients 60 and +, start Rx when BP > 150/90* ¤ Patient < 60, start Rx when BP > 140/80 From National Heart, Lung Blood Institute SPRINT Study ¨ NIH supported study ¨ 9000+ subjects ¨ With at least one risk factor for CV disease ¨ Preliminary findings--- ¨ Adults 50 and older with HBP, targeting a SBP <120 reduced rates of CV events by 25%; reduced risk of death by 27% compared to a target of SBP 140. National Heart, Lung and Blood Institute Complex/Resistant Hypertension ¨ Resistant hypertension is defined as blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes, one of which should be a diuretic. ¨ Patients whose blood pressure is controlled with four or more medications are considered to have resistant hypertension. Complex Hypertension ¨ BP above goal- 140/90 most patients. 130/80 diabetics or renal disease. ¨ Confirmed on at least two occasions with appropriate size cuff. ¨ Adherence to appropriate 3 drug regiment including a diuretic.
    [Show full text]
  • Initial Approach to Hypertension in the Hemodynamics Unit: Review Article
    REVIEW ARTICLE Initial approach to hypertension in the hemodynamics unit: review article Abordagem inicial da hipertensão arterial sistêmica em unidade de hemodinâmica: artigo de revisão Gustavo Teixeira Fulton Schimit1, José Manoel da Silva Silvestre2, Wander Eduardo Sardinha2, Eduardo Durante Ramires2, Domingos de Morais Filho2, Guilon Otávio Santos Tenório1, Fernando Barbosa Trevisan1 Abstract Correct identification and early management of hypertensive disorders should be a part of the therapeutic repertoire of every professional working in hemodynamics units. Based on recent publications, this study aims to propose a practical approach to the identification and early management of these disorders in this type of service. Keywords: hypertension; blood pressure; therapeutics; antihypertensive agents. Resumo O reconhecimento correto e manejo inicial das síndromes hipertensivas devem fazer parte do arsenal terapêutico de todo profissional que trabalhe em unidade de hemodinâmica. Este trabalho tem por objetivo, baseado em publicações recentes, propor uma abordagem prática para identificação e manejo inicial destes agravos nessa unidade. Palavras-chave: hipertensão; pressão arterial; terapêutica; anti-hipertensivos. 1Hospital Universitário Regional do Norte do Paraná, Londrina, PR, Brazil. 2Departamento de Clínica Cirúrgica, Universidade Estadual de Londrina – UEL, Londrina, PR, Brazil. Conflict of interest: No conflicts of interest declared concerning the publication of this article. Submitted on: 01.21.12. Accepted on: 03.25.13. The study was carried out at Hospital Universitário da Universidade Estadual de Londrina – UEL, Londrina, PR, Brazil. J Vasc Bras. 2013 Jun; 12(2):133-138 133 Hypertension in the hemodynamics unit INTRODUCTION been objectively adopted for the definition of normal Constant technical advances in the profession, blood pressure, and increases of 20/10 mm Hg above as well as in materials and new technologies, have this level double the risk of cardiovascular diseases11.
    [Show full text]
  • 3 Blood Pressure and Its Measurement
    Chapter 3 / Blood Pressure and Its Measurement 49 3 Blood Pressure and Its Measurement CONTENTS PHYSIOLOGY OF BLOOD FLOW AND BLOOD PRESSURE PHYSIOLOGY OF BLOOD PRESSURE MEASUREMENT POINTS TO REMEMBER WHEN MEASURING BLOOD PRESSURE FACTORS THAT AFFECT BLOOD PRESSURE READINGS INTERPRETATION OF BLOOD PRESSURE MEASUREMENTS USE OF BLOOD PRESSURE MEASUREMENT IN SPECIAL CLINICAL SITUATIONS REFERENCES PHYSIOLOGY OF BLOOD FLOW AND BLOOD PRESSURE The purpose of the arterial system is to provide oxygenated blood to the tissues by converting the intermittent cardiac output into a continuous capillary flow and this is achieved by the structural organization of the arterial system. The blood flow in a vessel is basically determined by two factors: 1. The pressure difference between the two ends of the vessel, which provides the driving force for the flow 2. The impediment to flow, which is essentially the vascular resistance This can be expressed by the following formula: 6P Q = R where Q is the flow, 6P is the pressure difference, and R is the resistance. The pressure head in the aorta and the large arteries is provided by the pumping action of the left ventricle ejecting blood with each systole. The arterial pressure peaks in systole and tends to fall during diastole. Briefly, the peak systolic pressure achieved is determined by (see Chapter 2): 1. The momentum of ejection (the stroke volume, the velocity of ejection, which in turn are related to the contractility of the ventricle and the afterload) 2. The distensibility of the proximal arterial system 3. The timing and amplitude of the reflected pressure wave When the arterial system is stiff, as in the elderly, for the same amount of stroke output, the peak systolic pressure achieved will be higher.
    [Show full text]
  • Quality Control of the Foot Revascularization Using Indocyanine Green Fluorescence Imaging
    World J Surg (2017) 41:1919–1926 DOI 10.1007/s00268-017-3950-6 ORIGINAL SCIENTIFIC REPORT Quality Control of the Foot Revascularization Using Indocyanine Green Fluorescence Imaging 1 1 1 1 Nicla Settembre • Petteri Kauhanen • Anders Alba¨ck • Kristyna Spillerova • Maarit Venermo1 Published online: 6 March 2017 Ó Socie´te´ Internationale de Chirurgie 2017 Abstract Objectives Critical limb ischemia (CLI) is a clinical diagnosis, confirmed by objective tests, usually ankle-brachial index (ABI), toe pressure (TP) and TcPO2. Furthermore, the anatomical lesions in patients affected by CLI were visualized by ultrasound, angiography, CTA, or MRA. Indocyanine green fluorescence imaging (ICG-FI) is a diagnostic modality for assessing foot perfusion. We aimed to study the usefulness of ICG-FI in the quality control of revascularization. Materials and methods One hundred and four CLI limbs in 101 patients were studied with ICG-FI using SPY Elite before and after open or endovascular revascularization. ABI and TP were also measured. After ICG-FI, assessment of circulation was done using time–intensity curve derived from the two regions of interest the one being in the plantar side of the foot and the other in the dorsal side of the foot. Three parameters were derived from the curves: maximum intensity (the absolute value of the maximum intensity); intensity rate (the value from the time–intensity curve describing the increase in maximum intensity/s) and SPY10 (the intensity achieved during the first 10 s after the foot starts to gain intensity). Results Sixty-two limbs presented category 3 of Rutherford classification, 12 limbs category 4, and 30 limbs category 5.
    [Show full text]
  • The Effect of Pseudoephedrine on Blood Pressure in Patients With
    The Effect Of Pseudoephedrine On Blood Pressure J Am Board Fam Pract: first published as 10.3122/jabfm.4.4.201 on 1 July 1991. Downloaded from In Patients With Controlled, Uncomplicated Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial John G. Bradley, M.D., Ken]. Kallai~ Ph.D., John N. Dorsch, M.D., andJoan Fox, R.N. Abslrtlet: Pseudoephedrine is frequendy used as a decongestant. Because of concern about 1be safety of pseudoephedrine in hypertensive patients, a clinical1rial was conducted to detennine whether blood pressure control was actuallya1fected by 1bis drug in a selected group of patients with hypertension. 1Wenty-nine patients wi1b controlled, uncomplicated hypertension, who received drug therapy and ranged in age from 25 to 50 years, were randomized to a treatment or a control group. Subjects took eI1ber 60 mg of pseudoephedrine or placebo capsules four times a day for 3 days. From 0800 hours until 2200 hours each day, the subjects obtained hourly blood pressure measurements using a porlable sphygmomanometer. An analysis of variance wi1b repeated measures was calculated to determine group differences for systolic and diastoUc readings. No statistically or clinically signiftcant differences were found. 1berapeu1ic: doses of pseudoephedrine did not adversely affect control of hypertension in 1bese selected patients. 0 Am Board Fam Pract 1991; 4:201-6.) Pseudoephedrine, phenylpropanolamine, and in hypertensive patients. While no adverse effect phenylephrine are oral sympathomimetic agents was found,IO this study was uncontrolled, a com­ commonly used as decongestants in prescription bination of drugs was used, and patient compli­ and over-the-counter preparations. Long-stand­ ance was unverified.
    [Show full text]
  • Pseudo-Hypertension in the Elderly: Still Hazy, After All These Years*
    Journal of Human Hypertension (1997) 11, 621–623 1997 Stockton Press. All rights reserved 0950-9240/97 $12.00 COMMENTARY Pseudo-hypertension in the elderly: still hazy, after all these years* JD Spence Departments of Clinical Neurological Sciences Internal Medicine, and Pharmacology and Toxicology, University of Western Ontario, Canada Keywords: pseudohypertension; blood pressure measurement; elderly (*with apologies to Simon and Garfunkel) The study reported in a recent issue of the Journal of and 12 Osler-negative (OM−) patients matched for Human Hypertension by Wright and Looney1 raises age and sex, they found no significant difference important issues about the difficulty of obtaining between the two groups; the over-estimation of dias- accurate measurements of blood pressure (BP), parti- tolic pressure by the cuff was 18.4 + 15.7 in the OM+, cularly in the elderly. How common is pseudohy- and 12 + 5.8 mm Hg in the OM−. They found, as did pertension, and how can it be reliably detected short we4 and Messerli et al,2 that there was a good corre- of doing intra-arterial BP measurements? It is inter- lation between the pulse wave velocity and the mag- esting that these issues remain unresolved, after 20 nitude of cuff artifact. years. Lewis et al5 did intra-arterial pressures in 15 nor- They studied Osler’s manoeuver, the sign of cuff motensives and 21 hypertensive elderly patients artifact due to arterial stiffness described by Mes- (age 65–89; mean age was 79 for the normotensives serli et al2 and so named because Osler, in his 1892 and 76 for the hypertensive group).
    [Show full text]
  • Clinical Appraisal of Arterial Stiffness: Heart: First Published As 10.1136/Hrt.2005.067025 on 9 December 2005
    Heart Online First, published on December 9, 2005 as 10.1136/hrt.2005.067025 1 Clinical appraisal of arterial stiffness: Heart: first published as 10.1136/hrt.2005.067025 on 9 December 2005. Downloaded from The Argonauts in front of the Golden Fleece Charalambos Vlachopoulos, Konstantinos Aznaouridis, Christodoulos Stefanadis. 1st Department of Cardiology, University of Athens Medical School, Hippokration Hospital, Athens, Greece Wordcount: 3594 (excluding Tables, Figure legends and References) http://heart.bmj.com/ Keywords: arterial stiffness, wave reflection, arterial elastic properties, aorta, peripheral vessels on September 25, 2021 by guest. Protected copyright. Corresponding author: Christodoulos Stefanadis 9 Tepeleniou Str. Paleo Psychico, 154 52 Athens, Greece Tel: + 30 210 770 3052 Fax: + 30 210 748 5039 e-mail: [email protected] Copyright Article author (or their employer) 2005. Produced by BMJ Publishing Group Ltd (& BCS) under licence. 2 The interest for evaluation of arterial elastic properties is growing during recent years Heart: first published as 10.1136/hrt.2005.067025 on 9 December 2005. Downloaded from impressively and in parallel with the widespread availability of noninvasive methods for assessment of arterial stiffness. In this article we discuss the current evidence concerning the clinical value of estimating arterial stiffness (mainly of large, elastic-type arteries, such as the aorta and the carotids) in the contemporary era of cardiovascular (CV) medicine. In this context, one has to keep in mind that the clinical
    [Show full text]
  • ACCF/AHA 2011 Expert Consensus Document on Hypertension in The
    Journal of the American College of Cardiology Vol. 57, No. 20, 2011 © 2011 by the American College of Cardiology Foundation and the American Heart Association, Inc. ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.008 EXPERT CONSENSUS DOCUMENT ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension Writing Wilbert S. Aronow, MD, FACC, Co-Chair* Eduardo Ortiz, MD, MPH† Committee Jerome L. Fleg, MD, FACC, Co-Chair† Efrain Reisin, MD, FASN** Members Carl J. Pepine, MD, MACC, Co-Chair* Michael W. Rich, MD, FACC†† Douglas D. Schocken, MD, FACC, FAHA‡‡ Nancy T. Artinian, PHD, RN, FAHA‡ Michael A. Weber, MD, FACC§§ ʈʈ George Bakris, MD, FASN Deborah J. Wesley, RN, BSN Alan S. Brown, MD, FACC, FAHA‡ *American College of Cardiology Foundation Representative; †Na- Keith C. Ferdinand, MD, FACC§ tional Heart, Lung, and Blood Institute; ‡American Heart Association ʈ Representative; §Association of Black Cardiologists Representative; Mary Ann Forciea, MD, FACP ʈAmerican College of Physicians Representative; ¶American Academy William H. Frishman, MD, FACC* of Neurology Representative; #European Society of Hypertension Representative; **American Society of Nephrology Representative; Cheryl Jaigobin, MD¶ ††American Geriatrics Society Representative; ‡‡American Society for Preventive Cardiology Representative; §§American Society of Hyper- John B. Kostis, MD, FACC tension Representative; ʈʈACCF Task Force on Clinical Expert Con- Giuseppi Mancia, MD# sensus Documents Representative.
    [Show full text]
  • Measurement of Blood Pressure
    Touro Scholar NYMC Faculty Publications Faculty 2-1-2017 Measurement of Blood Pressure Wilbert S. Aronow New York Medical College Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons Recommended Citation Aronow, W. S. (2017). Measurement of Blood Pressure. Annals of Translational Medicine, 5 (3), 49. https://doi.org/10.21037/atm.2017.01.09 This Editorial is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact [email protected]. Editorial Page 1 of 3 Measurement of blood pressure Wilbert S. Aronow Cardiology Division, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA Correspondence to: Wilbert S. Aronow, MD, FACC, FAHA. Professor of Medicine, Cardiology Division, Westchester Medical Center and New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595, USA. Email: [email protected]. Submitted Dec 11, 2016. Accepted for publication Dec 13, 2016. doi: 10.21037/atm.2017.01.09 View this article at: http://dx.doi.org/10.21037/atm.2017.01.09 Hypertension is a major risk factor for cardiovascular discuss the appropriate measurement of blood pressure. events and mortality (1-4). Hypertension occurs in 69% Hypertension is diagnosed if the blood pressure of individuals with first myocardial infarction (5), 77% of is elevated on at least three different blood pressure individuals with first stroke (5), 74% of individuals with heart measurements taken on two or more office visits (1,2).
    [Show full text]
  • Out-Of-Clinic Blood Pressure Testing in Primary Care
    Out-of-clinic blood pressure testing in primary care Out-of-clinic blood pressure monitoring is KEY practice points: increasingly regarded as a routine component of cardiovascular risk management. This is because it Out-of-clinic blood pressure measurements more accurately reflect a patient’s true blood pressure than do is a better predictor of cardiovascular events and clinic-based measurements and improve the quality of mortality than clinic-based measurements. General shared management decisions practices that use this technique can provide Consider out-of-clinic blood pressure testing to “rule-out” patients with more accurate cardiovascular risk the possibility of white-coat hypertension before initiating assessments and help them to make better decisions antihypertensive treatment about their health. Prescribers are also able to Out-of-clinic blood pressure testing can be used to more titrate blood pressure treatment regimens more accurately guide management once antihypertensive accurately using out-of-clinic measurements than treatment has been initiated if management was guided solely by clinic-based Consider out-of-clinic blood pressure testing for patients blood pressure assessments. Only validated devices with low cardiovascular risk, e.g. younger patients, where are recommended for the measurement of blood there is a clinical suspicion of masked hypertension pressure. Out-of-clinic blood pressure testing includes 24-hour ambulatory testing, where the patient wears an automated device, as well as home-based measurements performed by the patient. Ambulatory blood pressure monitoring is available as an outpatient test by DHBs, privately by some cardiologists or devices may be purchased by general practices. Home blood pressure testing devices are relatively inexpensive and validated devices can be purchased by patients or practices.
    [Show full text]
  • Shock, Resuscitation, and Surgical Critical Care
    SHOCK, RESUSCITATION, AND SURGICAL CRITICAL CARE PART A: SHOCK AND RESUSCITATION COMPETENCY-BASED KNOWLEDGE OBJECTIVES: 1. Define shock, categorize it based upon type, explain the etiology and pathophysiology of each type of shock: a. Cardiogenic b. Hypovolemic c. Distributive (septic, anaphylactic, neurogenic, and adrenal insufficiency mediated) d. Obstructive (cardiac tamponade, tension pneumothorax, pulmonary embolus) 2. Summarize the clinical presentation and hemodynamic parameters associated with each type of shock using clinical terms, such as heart rate, respiratory rate, and blood pressure and filling pressures. 3. Propose an algorithm for diagnosing and initiating treatment for each shock type. a. Cardiogenic b. Hypovolemic c. Distributive (septic, anaphylactic, neurogenic, and adrenal insufficiency mediated) d. Obstructive (cardiac tamponade, tension pneumothorax, pulmonary embolus) 4. Discuss the pathophysiology, including the mechanism of arrest, for each of the following situations: a. Acute myocardial infarction b. Acute dysrhythmia c. Congestive heart failure d. Hypovolemic shock (blood loss, dehydration) e. Burns f. Hemorrhagic shock (non-traumatic) g. Septic shock h. Anaphylactic shock (envenomation, drug related) i. Acute adrenal insufficiency j. Penetrating or blunt trauma (1) Tension pneumothorax (2) Pericardial tamponade (3) Hemorrhagic shock k. Hypothermia l. Substance abuse m. Electrical injury n. Suffocation o. Acute stroke 5. Explain the indications for and the pharmacokinetics of each of the following drugs: a. Lidocaine j. Vasopressin b. Digoxin k. Nitroglycerin c. Metoprolol l. Amrinone d. Diltiazem m. Milrinone e. Pronestyl n. Levophed f. Amiodarone o. Phenylephrine g. Dopamine p. Epinephrine h. Dobutamine i. Adenosine(Adenocard®) 6. Summarize the indication and appropriate technique for cardiac support, pressors, and Circulatory Assist Devices (IABP, LVAD, RVAD).
    [Show full text]